Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook
Edwards Lifesciences Corp (NYSE:EW) reported second-quarter sales of $1.37 billion, flat compared to 2Q21, missing the consensus of $1.4 billion.…
Truist Securities Maintains Buy on Edwards Lifesciences, Lowers Price Target to $120
Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $140 to $120.
Expert Ratings for Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter:
Looking Into Edwards Lifesciences’s Recent Short Interest
Edwards Lifesciences's (NYSE:EW) short percent of float has fallen 64.56% since its last report. The company recently reported that it has 6.21 million shares sold short, which is 1.01% of all regular shares that are available for trading.
Stifel Maintains Buy on Edwards Lifesciences, Lowers Price Target to $115
Stifel analyst Rick Wise maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $128 to $115.
Morgan Stanley Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $119
Morgan Stanley analyst Cecilia Furlong maintains Edwards Lifesciences (NYSE:EW) with a Overweight and lowers the price target from $136 to $119.
Here’s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 17.08% on an annualized basis producing an average annual return of 23.24%. Currently, Edwards Lifesciences has a market capitalization of $60.18 billion.
S. Korea’s Yonhap News Agency Reported N. Korea Fired Artillery Shots Sunday, Presumably From Multiple Rocket Launchers
https://en.yna.co.kr/view/AEN20220710002952325?input=tw
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 10 years by 7.85% on an annualized basis producing an average annual return of 18.65%. Currently, Edwards Lifesciences has a market capitalization of $59.55 billion.